ArticleGeneral thoracic and cardiovascular surgery2025
Trends in serum KL-6 levels following lung transplantation for interstitial lung diseases.
Article in General thoracic and cardiovascular surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the changes in Krebs von den Lungen-6 (KL-6) levels pre- and post-lung transplantation for interstitial lung disease and to determine the connection between changes in KL-6 levels and chronic lung allograft dysfunction.
methodsEighty-two lung transplantation procedures were performed in interstitial lung disease patients between January 2008 and December 2019. We compared changes in KL-6 levels before and after transplantation in two groups: unilateral and bilateral lung transplant groups. Additionally, KL-6 levels just before or at the onset of chronic lung allograft dysfunction were compared to the lowest post-transplant levels.
resultsIn total, 28 female and 49 male patients (median age: 54 years; range 22-64; 42 and 35 patients underwent unilateral and bilateral lung transplantations, respectively) were enrolled. The post-transplant observation period ranged from 8 to 163 (median: 64.2) months. KL-6 levels decreased in 76 patients (98.7%). Notably, the KL-6 level was lower in the bilateral lung transplantation group than in the unilateral lung transplantation group. Moreover, KL-6 levels were higher just before or at the onset of chronic lung allograft dysfunction than the lowest post-transplant levels. These levels were significantly higher than the highest post-transplant levels observed in the non-chronic lung allograft dysfunction group.
conclusionsOur findings suggest that KL-6 levels decrease in interstitial lung disease patients following lung transplantation, with a greater reduction in KL-6 levels observed in bilateral lung transplantation compared to unilateral lung transplantation. Elevated serum KL-6 levels were associated with chronic lung allograft dysfunction, highlighting its utility as a diagnostic biomarker.
Indexed as
Identifiers
39992597What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.